MANILA, Philippines – Molnupiravir, an antiviral drug used in the treatment of mild to moderate COVID-19, is now available to patients prescribed to take it through the Bayanihan E-Konsulta program in the Vice President’s office (OVP).
Vice President Leni Robredo announced this Monday evening in a post on her personal Facebook account, saying she had signed a memorandum of understanding with QualiMed Health Network to help patients who have been prescribed molnupiravir.
Robredo said the OVP will issue a letter of guarantee from Bayanihan E-Konsulta, its telemedicine program, which virtually reviews patient cases.
Bayanihan E-Konsulta patients could receive part of the first shipment of molnupiravir manufactured in Southeast Asia, which arrived in the Philippines on November 17.
“The QualiMed facilities will then assess and prescribe the drug to the patient,” said Robredo.
MOLNUPIRAVIR is now available for our patients who can be prescribed to take them under our Bayanihan E-Konsulta…
Posted by Leni Gerona Robredo on Monday, November 22, 2021
“We are truly touched and grateful to the QualiMed Health Network for trusting us with this partnership, helping us expand our reach by providing aid to more of our Kababayans in need. Maraming, maraming salamat po! she added.
In the previous weeks, several prominent figures lobbied for the use of molnupiravir, which is seen as a change in the management of COVID-19 cases, as patients would no longer need to be hospitalized in the early stages. of infection.
On November 9, another presidential candidate, Senator Panfilo Lacson, asked the Food and Drug Administration (FDA) to authorize the commercial sale of molnupiravir. In response, FDA chief executive Eric Domingo said molnupiravir was already available under a special compassionate license.
However, Domingo also assured that the FDA is working on evaluating the Emergency Use Authorization (EUA) and Product Registration Certificate (CPR) applications for molnupiravir.
READ: Lacson urges FDA to allow commercial sale and use of anti-COVID pill
Molnupiravir, a COVID-19 antiviral pill jointly developed by Merck and US-based Ridgeback Biotherapeutics, has provided possible early-stage treatment for COVID-19 infections, which in turn would prevent severe cases and hospitalizations .
The UK was the first country to approve use of the pill, which will be rolled out during a drug trial phase in November.
READ: UK to roll out COVID-19 antiviral drug trial this month – Health Security Agency https://newsinfo.inquirer.net/1512124/uk-to-roll-out-covid-19-antiviral-drug -trial-this- month-health-safety-agency # ixzz7Bi2Pr4bI
READ: Britain approves Merck’s COVID-19 pill as world premiere https://newsinfo.inquirer.net/1510634/britain-approves-mercks-covid-19-pill-in-world-first#ixzz7Bi2Yvpb2
Currently, the number of COVID-19 in the country has improved, with the infection rate continuously decreasing and hospitals being decongested after nearly filling again in the last wave from August to September.
However, there are fears that the good trend may be short-lived if people don’t stick to health protocols. Over the past weekends, social media users have noticed busier roads and higher numbers of children in public spaces after the national government put Metro Manila under Alert Level 2.
READ: Complacency below Alert Level 2 worries DOH https://newsinfo.inquirer.net/1511455/complacency-under-alert-level-2-worries-doh
QualiMed Health Network, telemedicine, Bayanihan E-Konsulta, COVID-19 case, COVID-19 pill, molnupiravir, Food and Drug Administration, FDA, elections 2022, # 2022candidates,
Subscribe to our daily newsletter
Subscribe to INQUIRER PLUS to access The Philippine Daily Inquirer and over 70 other titles, share up to 5 gadgets, listen to the news, download from 4 a.m. and share articles on social media. Call 896 6000.